A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know
Key Points
The transaction involved 3,000 shares with a value of $161,700 on August 14.
The sale reduced West's direct equity position by 8%.
The liquidation was executed entirely from direct holdings under a Rule 10b5-1 trading plan adopted on May 15.
This routine divestment occurred as the stock reflected a -27% return over the 12 months ending August 14, before a major stock surge.
Nadja West, a director at Tempus AI, Inc. (NASDAQ:TEM), sold 3,000 shares of Class A Common Stock on August 14 at $53.90 per share, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $161,700 |
| Shares sold | 3,000 |
| Post-transaction shares (directly held) | 34,981 |
| Post-transaction value | ~$1.8 million |
Transaction value based on SEC Form 4 weighted average sale price ($53.90); post-transaction value based on the August 14 market close ($52.10).
Key questions
- What is the context of the Rule 10b5-1 plan?
The transaction was executed under a trading plan established by West on May 15, which allows insiders to schedule stock sales in advance to manage personal portfolios while minimizing concerns regarding material non-public information. - What is the company's current operational focus?
Chicago-based Tempus AI operates a healthcare technology platform that facilitates bi-directional integration between clinical laboratory diagnostics and physician desktops, while also providing clinical applications for managing next-generation sequencing tests. - How do the company's trailing financials appear?
As of the latest reporting, the company generated $1.4 billion in trailing twelve-month revenue but recorded a net income loss of $254.4 million. - How does this sale affect the director's long-term interest in the firm?
Following this disposition of 3,000 shares, West retains a direct ownership stake of 34,981 shares of Class A Common Stock, maintaining significant exposure to the company's performance.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-17) | $51.64 |
| Market Capitalization | $9.0 billion |
| Revenue (TTM) | $1.4 billion |
| Net Income (TTM) | -$254.4 million |
Company Snapshot
- Tempus AI operates a closed-loop, full-stack healthcare technology platform that integrates clinician workflows with laboratory diagnostic capabilities, analytics, and multimodal data repositories, generating revenue through diagnostic testing services and platform licensing to healthcare providers.
- The company operates on a technology-enabled services model, leveraging its proprietary Tempus platform and Hub clinical application to deliver next-generation sequencing (NGS) tests and diagnostic insights that drive adoption among physicians and healthcare systems.
- The company primarily serves oncologists, pathologists, and healthcare systems seeking advanced diagnostic capabilities, with a focus on precision medicine and genomic testing applications across the United States healthcare market.
Tempus AI is a healthcare technology company headquartered in Chicago, with a market capitalization of $9.0 billion and approximately 3,800 employees. The company has achieved TTM revenue of $1.4 billion while investing heavily in platform development and market expansion, as evidenced by its current net loss position. Tempus AI's competitive differentiation stems from its integrated platform architecture that combines clinical workflow optimization with advanced diagnostic analytics, positioning it as a comprehensive solution provider in the precision medicine and genomic testing landscape.
What this transaction means for investors
West sold four days before Tempus stock skyrocketed on news that Moderna and Merck's cancer vaccine hit its goals in its first-ever late-stage trial, and the transaction ran through a 10b5-1 plan she set up back in May, long before anyone knew what August would bring. Plus, the size is small against the 34,981 she still holds directly, and there's no story in the timing at all.
More importantly for long-term investors, as a director, West sits on the board that will eventually vote on integrating the pending $1.5 billion Personalis acquisition, the deal now driving most of the excitement in this stock, since Personalis makes the genomic sequencing technology used in the Moderna vaccine. That's a bigger lever on shareholder value than any scheduled sale a board member makes under a pre-set plan. Meanwhile, the business she's overseeing had a strong second quarter, with revenue up 22% to $382.5 million and the company reporting its first GAAP profit. Despite still being down 10% over the past year, continued execution could mean the stock's recent turnaround has legs, and ultimately, that’ll matter more than routine transactions like this one.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tempus AI. The Motley Fool has a disclosure policy.